The cover story focuses on the first FDA-approved gene-transfer therapy, Novartis’s Kymriah, and other CAR T-cell products in development.
Cover Story: On 30 August, the FDA approved Novartis’s Kymriah, the first gene therapy for the treatment of pediatric and young-adult patients with relapsed and refractory ALL. This is the first FDA-approved gene-transfer therapy, but there are a number of other CAR T-cell products in development.
Feature: CRISPR’s power lies in its relative simplicity and precision, and it is expected to have profound implications for agriculture and the treatment of disease.
Special Report: While biopharmaceutical drugs have become standard therapy for multiple diseases, they require new manufacturing techniques both at the facility and throughout the supply network.